Joe William Edward Moss

Dr. Joe William Edward Moss

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2016 in Nature Reviews Cardiology
Verified
Journal Article
Closed access
PDF file
JMJoe William Edward Moss
Joe William Edward Moss
DRDipak P. Ramji
Dipak P. Ramji

30 June 2016 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
JMJoe William Edward Moss
Joe William Edward Moss
DRDipak P. Ramji
Dipak P. Ramji
Atherosclerosis, the primary cause of cardiovascular disease (CVD), is a chronic inflammatory disorder in the walls of medium and large arteries. CVD is currently responsible for about one in three...

16 December 2020 in International Wound Journal
Verified
Journal Article
Open access
PDF file
JTJoshua Phillip Totty
Joshua Phillip Totty
JMJoe William Edward Moss
Joe William Edward Moss
EBErin Barker
Erin Barker
SMStuart James Mealing
Stuart James Mealing
JPJohn William Posnett
John William Posnett
GSGeorge Edward Smith
George Edward Smith
Surgical site infections (SSI) substantially increase costs for healthcare providers because of additional treatments and extended patient recovery. The objective of this study was to assess the cost and health‐related quality of life impact of SSI, from the perspective of a large teaching hospital in England. Data were available for 144 participants undergoing clean or clean‐contaminated vascular surgery. SSI development, length of hospital stay, readmission, and antibiotic use were recorded over a 30‐day period. Patient‐reported EQ‐5D scores were obtained at baseline, day 7 and day 30. Linear regressions were used to control for confounding variables. A mean SSI‐associated length of stay of 9.72 days resulted in an additional cost of £3776 per patient (including a mean antibiotic cost of £532). Adjusting for age, smoking status, and procedure type, SSI was associated with a 92% increase in length of stay (P < 0.001). The adjusted episode cost was £3040. SSI reduced patient utility between baseline and day 30 by 0.156 (P = 0.236). Readmission rates were higher with SSI (P = 0.017), and the rate to return to work within 90 days was lower. Therefore, strategies to reduce the risk of surgical site infection for high‐risk vascular patients should be investigated.

1 May 2018 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Open access
JMJoe William Edward Moss
Joe William Edward Moss
JWJessica O. Williams
Jessica O. Williams
DRDipak P. Ramji
Dipak P. Ramji
Atherosclerosis, a chronic inflammatory disorder of medium and large arteries and an underlying cause of cardiovascular disease (CVD), is responsible for a third of all global deaths. Current treatments for CVD, such as optimized statin therapy, are associated with considerable residual risk and several side effects in some patients. The outcome of research on the identification of alternative pharmaceutical agents for the treatment of CVD has been relatively disappointing with many promising leads failing at the clinical level. Nutraceuticals, products from food sources with health benefits beyond their nutritional value, represent promising agents in the prevention of CVD or as an add-on therapy with current treatments. This review will highlight the potential of several nutraceuticals, including polyunsaturated fatty acids, flavonoids and other polyphenols, as anti-CVD therapies based on clinical and pre-clinical mechanism-based studies.

6 June 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DMD.R. Michael
D.R. Michael
TDT. S. Davies
T. S. Davies
JMJoe William Edward Moss
Joe William Edward Moss
DCD. Lama Calvente
D. Lama Calvente
DRDipak P. Ramji
Dipak P. Ramji
THT. R. Hughes
T. R. Hughes
Hypercholesterolaemia is a major risk factor for cardiovascular disease and it has been found that some probiotic bacteria possess cholesterol-lowering capabilities. In this study, the ability of the Lab4 probiotic consortium to hydrolyse bile salts, assimilate cholesterol and regulate cholesterol transport by polarised Caco-2 enterocytes was demonstrated. Furthermore, in wild-type C57BL/6J mice fed a high fat diet, 2-weeks supplementation with Lab4 probiotic consortium plus Lactobacillusplantarum CUL66 resulted in significant reductions in plasma total cholesterol levels and suppression of diet-induced weight gain. No changes in plasma levels of very low-density lipoprotein/low-density lipoprotein, high-density lipoprotein, triglycerides, cytokines or bile acids were observed. Increased amounts of total and unconjugated bile acids in the faeces of the probiotic-fed mice, together with modulation of hepatic small heterodimer partner and cholesterol-7α-hydroxylase mRNA expression, implicates bile salt hydrolase activity as a potential mechanism of action. In summary, this study demonstrates the cholesterol-lowering efficacy of short-term feeding of the Lab4 probiotic consortium plus L. plantarum CUL66 in wild-type mice and supports further assessment in human trials.

1 January 2015 in World Journal of Experimental Medicine
Verified
Journal Article
Open access
JMJoe William Edward Moss
Joe William Edward Moss
DRDipak P. Ramji
Dipak P. Ramji
Interferon-γ: Promising therapeutic target in atherosclerosis